UCB (OTCMKTS:UCBJY) is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.
The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome. In addition to these established products, UCB maintains a robust pipeline of biologics and small molecules, pursuing next-generation treatments across immunology and neurology through both in-house research and strategic collaborations.
With operations spanning more than 40 countries, UCB combines global reach with a network of research, development and manufacturing sites in Europe, North America and Asia. This geographic footprint enables the company to conduct late-stage clinical trials, ensure regulatory compliance across diverse markets and maintain a reliable supply chain to meet patient needs worldwide.
UCB’s governance framework comprises a board of directors and an executive leadership team committed to innovation, patient-centric development and sustainable growth. Through ongoing investment in research, strategic partnerships and a focus on scientific excellence, the company aims to deliver transformative therapies that improve quality of life for patients with severe and complex diseases.
